FDA Panel Debates Efficacy of Multi-Cancer Blood Test
AI-generated context summary requested by a Free News Reader user. Sourced via Gemini from publicly available information — no paywalled content was accessed.
You hit a paywall. Here’s the context on this topic based on publicly available information. We did not access any paywalled content. View original article.
FDA Panel Debates Efficacy of Multi-Cancer Blood Test
- A divided FDA advisory committee recently voted 6-4 in favor of the effectiveness of the Galleri blood test, designed to screen for over 50 types of cancer.
- Despite unanimous agreement on safety, some committee members, including Dr. Victor van Berkel, expressed reservations about the current data supporting the test's efficacy for early detection.
Full Summary — powered by AI
A U.S. Food and Drug Administration (FDA) advisory committee recently reviewed the Galleri multi-cancer early detection blood test, leading to a split decision on its effectiveness. The test, developed by Grail, aims to detect signals for over 50 types of cancer from a single blood sample, including many for which no routine screenings currently exist.
On Wednesday, September 23, 2026, the Molecular and Clinical Genetics Devices Panel voted 6-4 that the evidence supports Galleri’s ability to detect cancers in adults aged 50 and older. While all 10 voting members unanimously affirmed the test’s safety, the panel’s vote on whether the benefits outweigh the risks was 7-2, with one abstention. This advisory vote is a step towards potential FDA approval, though the agency is not bound by the panel’s recommendation and a final decision is anticipated in the coming months.
The Galleri test has been commercially available in the United States since 2021, but it has not yet received FDA approval. The test works by analyzing DNA fragments in a blood sample for methylation patterns that can indicate the presence of cancer. Proponents of the test, including Grail CEO Josh Ofman, highlight its potential to detect cancers at earlier stages, offering less invasive screening methods and increasing accessibility. However, concerns have been raised regarding the test’s efficacy, particularly in detecting early-stage cancers, and the potential for false-positive or false-negative results, which could lead to unnecessary procedures or a false sense of security.
A major trial conducted with England’s National Health Service (NHS), the NHS-Galleri trial, did not show a statistically significant reduction in late-stage cancer diagnoses for patients who took the Galleri test. This trial, which enrolled 142,250 adults aged 50 to 77, aimed to assess if the test could improve cancer detection. Despite this, Grail reported a favorable trend toward fewer stage III-IV cancers in a pre-specified group of 12 deadly cancers after the initial screening round. Experts like Dr. Victor van Berkel, while voting in favor, emphasized the need for more data to firmly establish the test’s effectiveness.